DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Cavernous Hemangioma of the Face — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCavernous Hemangioma of the Face maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cavernous hemangioma of the face is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta receptor 2 (TGFBR2) — TGFBR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-methoxypyridin-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5QIN · 1.57 Å · ligand N-{4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide (J2V). Experimental structure, not a prediction.
What the evidence adds up to
Cavernous hemangioma of the face is a benign vascular tumour, but it is about one-tenth as common as capillary hemangioma and much less likely to undergo spontaneous involution. It tends to have a more aggressive course and may cause complications related to its location. One case report describes a patient who developed a huge haematoma of the right face from a cavernous hemangioma. Another reports a 52-year-old man who had a hemangioma from childhood that grew over 45 years to cause extreme cosmetic deformity. No drug treatment is mentioned in any of these abstracts.
Diagnosis can be missed. A patient with a barely noticeable lump on the lower medial eyelid underwent two exploratory surgeries without a diagnosis, and additional exploratory surgeries were recommended by other ophthalmologists before an MRI finally confirmed an orbital cavernous hemangioma. The patient’s account emphasises that patients can contribute by doing research, being informed, asking questions, and seeking second or third opinions.
Management of cavernous hemangioma of the tongue in a 2-year-old and a 14-year-old child used different approaches, but the abstracts do not specify what those approaches were. No controlled trials, no drug interventions, and no quantitative outcomes such as response rates or survival are reported in any of these papers. What is missing is any clinical trial testing a drug for this condition, any systematic comparison of treatment approaches, and any data on patient stratification by lesion size, location, or age.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · 2014 · 19 citations · open access
Cavernous Hemangioma of Tongue: Management of Two Cases
AbstractHemangiomas are benign tumours of infancy and childhood, most commonly located in the head and neck region and occur more frequently in the lips, tongue and palate. The treatment depends upon lesion location, size and evolution stage and the patient's age. This paper describes the management of cavernous hemangioma in a 2 -year -old child and 14 -year -old child using different approaches.
The Journal of Health Design · 2019 · 0 citations · open access
How cavernous hemangioma went undiagnosed and lessons learned
AbstractA barely noticeable lump on the bottom medial part of my right eyelid went undiagnosed after two exploratory surgeries. Additional exploratory surgeries were recommended in subsequent consults with different ophthalmologists without anyone suggesting diagnostic tools (eg, MRI). An MRI ultimately confirmed a common condition called an orbital cavernous hemangioma. Patients can contribute to their patient experience by doing research, being informed, asking questions, and getting a second, even third, opinion, if necessary.
Journal of Clinical Otolaryngology Head and Neck Surgery · 1995 · 0 citations · open access
A Case of Cavernous Hemangioma Formed Huge Hematoma of Right Face
AbstractHemangioma is the most common, localized, benign vascular tumor of the head and neck. Cavernous hemangioma is about one-tenth as common as capillary hemangioma, although congenital, is often not apparent at birth and may undergo a rapid growth phase during the first 6 months of life. Cavernous hemangioma is much less likely to undergo spontaneous involution and tends to have a more aggressive course, and may result in complications related to its location. The authors experienced a case of cavernous hemangioma formed huge hematoma of right face, so report this case with a review of literatures.
Otorhinolaryngology Clinics - An International Journal · 2013 · 0 citations
Large and Long Standing Cavernous Hemangioma of Cheek
AbstractABSTRACT Cavernous hemangiomas are relatively rare vascular malformations especially in an adult. The childhood hemangioma generally regresses spontaneously. We present the case report of a 52-year-old male patient, who had a hemangioma from the childhood and it had grown to such a large size so as to cause extreme cosmetic deformity for the patient. The long standing duration of almost 45 years and the extremely large size of the hemangioma make it a very rare case. How to cite this article Gupta N, Verma H. Large and Long Standing Cavernous Hemangioma of Cheek. Int J Otorhinolaryngol Clin 2013;5(2):91-93.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
